Quidel Ortho Corp, publicly traded as QDEL, is a leading manufacturer of diagnostic healthcare solutions that empower medical professionals to enhance patient care. Established in 1979 and headquartered in San Diego, California, Quidel Ortho Corp serves to provide reliable, rapid diagnostic testing solutions globally, ideal for a variety of healthcare settings.
These settings include hospitals, laboratories, physician offices, and clinics. The company's core mission is to support improved health outcomes by delivering innovative diagnostic tools that make a real difference in the healthcare sector.
Quidel Ortho Corp has a comprehensive product portfolio predominantly centered on infectious diseases, children's health, gastrointestinal diseases, autoimmune diseases, and bone health. It produces a broad array of diagnostic testing solutions, including immunoassays, molecular assays, and virology assays. These are provided under renowned brand names like Sofia®, QuickVue®, Lyra®, Triage®, InflammaDry®, and Solana®.
One of Quidel’s significant innovations is the various COVID-19 tests it has produced, including the first rapid antigen test to receive emergency use authorization from the FDA. This critical achievement illustrates the company's commitment to providing swift, reliable, and accessible COVID-19 testing efforts amidst the global pandemic.
Quidel Ortho Corp is consistently recognized for its innovation and excellence. The company possesses many FDA clearances and holds numerous patents related to its diagnostic healthcare advancements. Furthermore, its commitment to research and development is reflected in its ongoing collaborations with various universities, government centers, and commercial entities to further enhance its diagnostic product offerings.
As a public entity, Quidel Ortho Corp strongly values responsible conduct and transparency, adhering to stringent governance and compliance standards. It's dedicated to a corporate culture that emphasizes respect, integrity, and ethical behavior, supporting the well-being of patients, providers, employees, shareholders, and the communities in which it operates.
Overall, Quidel Ortho Corp plays an essential role in modern healthcare, providing diagnostic tools that enable healthcare professionals to provide better healthcare for their patients. Through its commitment to innovation, quality, and responsibility, the company continues to contribute positively to patient outcomes and the broader healthcare sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Quidelortho Corp has entered into Amendment No. 1 to its Credit Agreement on September 23, 2026. The article from Reuters, available through TradingView, reports this event. Full details are accessible to TradingView users.
QuidelOrtho Corporation announced an amendment to its credit agreement on September 23, 2026, resetting financial covenant thresholds and modifying interest rates through September 30, 2029. The amendment adjusts the maximum Consolidated Leverage Ratio and minimum Consolidated Interest Coverage Ratio over this period. It also updates interest rates for Term Loan A and the revolving credit facility, while Term Loan B rates remain unchanged.
Tejara Capital Ltd has acquired a new stake in QuidelOrtho Corporation (NASDAQ:QDEL) worth approximately $2.27 million, representing about 0.19% of the company. Despite this investment and QuidelOrtho beating recent quarterly earnings and revenue estimates, analyst sentiment remains cautious with a consensus rating of "Reduce" and an average price target of $13.62. Other institutional investors like T. Rowe Price Investment Management Inc. and BlackRock Inc. also hold significant stakes, with institutional investors collectively owning 99% of the stock.
Rice Hall James & Associates LLC has acquired a new stake in QuidelOrtho Corporation (NASDAQ:QDEL) worth approximately $18.63 million, representing 1.56% of the company. Other institutional investors have also adjusted their holdings in QuidelOrtho, with institutional ownership nearing 99%. Despite beating earnings expectations, the company faces a "Reduce" consensus rating from analysts, with a target price below its opening stock price.
QuidelOrtho (QDEL) saw its stock rise by 6.0% despite cutting its 2026 revenue guidance to US$2.52–2.60 billion from US$2.70–2.75 billion. The company reported narrower losses in Q2 2026, with sales of US$630.9 million, but faces ongoing challenges including persistent losses and a tight cash position. The new CFO, Micah Young, will oversee cost control and portfolio decisions as investors monitor the company's path to profitability by 2029.